Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms

International Journal of Cancer

Volumn 78, Issue 2, 1998, Pages 196-201

  Okada, Hideho ^a,b   Tahara, Hideaki ^a   Shurin, Michael R ^a   Attanucci, Jason ^a,b   Giezeman Smits, Katinka M ^a,b   Fellows, Wendy K ^a,b   Lotze, Michael T ^a   Chambers, William H ^a,b   Bozik, Michael E ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; BRAIN TUMOR; CANCER IMMUNIZATION; CANCER PREVENTION; DENDRITIC CELL; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, NEOPLASM; BONE MARROW CELLS; BRAIN NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; EPITOPES; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE SUBSETS; MICE; MICE, INBRED C57BL; OLIGOPEPTIDES;

EID: 0031685253     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19981005)78:2<196::AID-IJC13>3.0.CO;2-9     Document Type: Article

References (34)

1. ASHLEY, D.M., FAIOLA, B., NAIR, S., HALE, L. P., BIGNER, D.D. and GILBOA, E., Bone marrow-gene rated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J. exp. Med., 186, 1177-1182 (1997).
2. BAKKER, A.B., MARLAND, G., DE BOER, A.J., HUIJBENS, R.J., DANEN, E.H., ADEMA, G.J. and FIGDOR, G.G., Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanomaassociated antigen-derived epitopes by dendritic cells in vitro. Cancer Res., 55, 5330-5334 (1995).
3. BIGNER, D.D., PITTS, O.M. and WIKSTRAND, C.J., Induction of lethal experimental allergic encephalomyelitis in non-human primates and guinea pigs with human glioblastoma multiforme tissue. J. Neurosurg., 55, 32-42 (1981).
4. BLOOM, H.J.G., PECKHAM, M.J., RICHARDSON, A.E., ALEXANDER, P.A. and PAYNE, P.M., Glioblastoma multiforme: a controlled trial to assess the value of specific active immunotherapy in patients treated by radical surgery and radiotherapy. Brit. J. Cancer, 27, 253-267 (1973).
5. BÖGLER, O., HUANG, H.J., KLEIHUES, P. and CAVENEE, W.K., The p53 gene and its role in human brain tumors. Glia, 15, 308-327 (1995).
6. BOZIK, M.E., CHAMBERS, W.H., GILBERT, M. and LOTZE, M.T., Treatment of 9L gliosarcoma with IL-4 producing 9L vaccine. FASEB J., 10, A1413 (1996).
7. CHI, D.D., MERCHANT, R.E., RAND, R., CONRAD, A.J., GARRISON, D., TURNER, R., MORTON, D.L. and HOON, D.S., Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Amer. J. Pathol., 150, 2143-2152 (1997).
8. DE MICCO, C., Immunology of central nervous system tumors. J. Neuroimmunol., 25, 93-108 (1989).
9. FELTKAMP, M.C., SMITS, H.L., VIERBOOM, M.P., MINNAAR, R.P., DE JONGH, B.M., DRIJFHOUT, J.W., TER SCHEGGET, J., MELIEF, C.J. and KAST, M.W., Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Europ. J. Immunol., 23, 2242-2249 (1993).
10. FELTKAMP, M.C., VREUGDENHIL, G.R., VIERBOOM, M.P., RAS, E., VAN DER BURG, S.H., TER SCHEGGET, J., MELIEF, C.J. and KAST, W.M., Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Europ. J. Immunol., 25, 2638-2642 (1995).
11. FISK, B., BLEVINS, T.L., WHARTON, J.T. and IOANNIDES, C.G., Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. exp. Med., 181, 2109-2117 (1995).
12. FREI, K. and FONTANA, A., Antigen presentation in the CNS. Mol. Psychiatr., 2, 96-98 (1997).
13. GILBERTSON, R.J., JAROS, E., PERRY, R.H., KELLY, P.J., LUNEC, J. and PEARSON, A.D., Mitotic percentage index: a new prognostic factor for childhood medulloblastoma. Europ. J. Cancer, 33, 609-615 (1997).
14. GlLBERTSON, R.J., PEARSON, A.D., PERRY, R.H., JAROS, E. and KELLY, P.J., Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Brit. J. Cancer, 71, 413-411 (1995).
15. GORDON, L.B., NOLAN, S.C., CSERR, H.F., KNOPF, P.M. and HARLING-BERG, C.J., Growth of P511 mastocytoma cells in BALB/c mouse brain elicits CTL response without tumor elimination. J. Immunol., 159, 2399-2408 (1997).
16. HOUBIERS, J.G.A., NIJMAN, H.W., VAN DER BURG, S.H., DRIJFHOUNT, J.W., KENEMANS, P., VAN DE VELDE, C.J.H., BRAND, A., MOMBURG, F., KAST, W.M. and MELIEF, C.J.M., In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Europ. J. Immunol., 23, 2072-2077 (1993).
17. KALMAN, B. and LUBLIN, F.D., Immunopathogenic mechanisms in experimental allergic encephalomyelitis. Curr. Opin. Neurol. Neurosurg., 6, 182-188 (1993).
18. KRISTT, D.A. and YARDEN, Y., Differences between phosphotyrosine accumulation and Neu/ErbB-2 receptor expression in astrocytic proliferative processes. Implications for glial oncogenesis. Cancer, 78, 1272-1283 (1996).
19. MAHALEY, M.S., JR., BIGNER, D.D., DUDKA, L.F., WILDS, P.R., WILLIAMS, D.H., BOULDIN, T.W., WHITAKER, J.N. and BYNUM, M.S., Immunobiology of primary intracranial tumors. VII. Active immunization of patients with anaplastic human glioma cells: a pilot study. J. Neurosurg., 59, 201-207 (1983).
20. MAYORDOMO, J.I., ZORINA, T., STORKUS, W.J., ZITVOGEL, L., CELLUZZI, C., FALO, L.D., MELIEF, C.J., ILDSTAD, S.T., KAST, W.M., DELEO, A.B. and LOTZE, M.T., Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumor immunity. Nature (Med.), 1, 1297-1302 (1995).
21. MITCHELL, M.S., Relapse in the central nervous system in melanoma patients successfully treated with biomodulators. J. clin. Oncol., 7, 1701-1709 (1989).
22. MURPHY, J.B. and STURM, E., Conditions determining the transplantability of tissues in the brain. Rockefeller Inst. Med. Res., 21, 183-197 (1926).
23. NAGATA, Y., FURUGEN, R., HIASA, A., IKEDA, H., OHTA, N., FURUKAWA, K., NAKAMURA, H., KANEMATSU, T. and SHIKU, H., Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J. Immunol., 159, 1336-1343 (1997).
24. NEUMANN, H., BOUCRAUT, J., HAHNEL, C., MISGELD, T. and WEKERLE, H., Neuronal control of MHC class II inducibility in rat astrocytes and microglia. Europ. J. Neurosci., 8, 2582-2590 (1996).
25. NIJMAN, H.W., HOUBIERS, J.G.A., VAN DER BURG, S.H., VIERBOOM, M.P.M., KANEMANS, P., KAST, W.M. and MELIEF, C.J.M., Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides. J. Immunother., 14, 121-126 (1993).
26. SAAS, P., WALKER, P.R., HAHNE, M., QUIQUEREZ, A.L., SCHNURIGER, V., PERRIN, G., FRENCH, L., VAN MEIR, E.G., DE TRIBOLET, N., TSCHOPP, J. and DIETRICH, P.Y., Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J. clin. Invest., 99, 1173-1178 (1997).
27. + cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc. nat. Acad. Sci. (Wash.), 93, 10399-10404 (1996).
28. SCHMIDT, S., LININGTON, C., ZIPP, F., SOTGIU, S., DE WAAL MALEFYT, R., WEKERLE, H. and HOHLFELD, R., Multiple sclerosis: comparison of the human T-cell response to S100 beta and myelin basic protein reveal parallels to rat experimental autoimmune panencephalitis. Brain, 120, 1437-1445 (1997).
29. TROUILLAS, P., Immunologie et immunothérapie des tumeurs cérébrales. Etat actuel. Rev. Neurol. (Paris), 128, 23-38 (1973).
30. TSAI, V., SOUTHWOOD, S., SIDNEY, J., SAKAGUCHI, K., KAWAKAMI, Y., APPELLA, E., SETTE, A. and CELIS, E., Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J. Immunol., 158, 1796-1802 (1997).
31. WAKIMOTO, H., ABE, J., TSUNODA, R., AOYAGI, M., HIRAKAWA, K. and HAMADA, H., Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res., 56, 1828-1833 (1996).
32. WELLER, M. and FONTANA, A., The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Brain Res., 21, 128-151 (1995).
33. ZITVOGEL, L., MAYORDOMO, J.I., TJANDRAWAN, T., DELEO, A.B., CLARKE, M.R., LOTZE, M.T. and STORKUS, W.J., Therapy of murine tumors with tumor-peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation. and helper cell 1-associated cytokines. J. exp. Med., 183, 87-97 (1996).
34. ZORINA, T., MAYORDOMO, J.I., WATKINS, M., LOTZE, M.T., DELEO, A.B. and ILDSTAD, S.T., Culture of dendritic cells from murine bone marrow supplemented with GM-CSF and TNF-alpha. J. Immunother., 16, 247 (1994).